Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Abivax
company
About
Abivax is a pioneering biotech company.
- 11 - 50
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- €15M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2013
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€35M
Abivax has raised a total of
€35M
in funding over 2 rounds. Their latest funding was raised on
Oct 13, 2020 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 13, 2020 | Post-IPO Debt | €15M | 1 |
Kreos Capital
|
— | Detail |
| Jul 25, 2018 | Post-IPO Debt | €20M | 1 |
Kreos Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Abivax is funded by 1 investors.
Kreos Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Kreos Capital
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
